Concert pursues clinical data for drug delivery tech

Following last year's $1 billion pact with GlaxoSmithKline (NYSE: GSK), Concert Pharmaceuticals is continuing its drug delivery work and hoping the attract additional partners for its only clinical-stage program not covered by the GSK pact. Concert's technology, replacing hydrogen molecules in therapeutics with deuterium, can improve a drug's performance. Deuterium forms stronger bonds with a drugs other atoms, making it possible that patients could take lower drug doses and...